Patients Coming Off Slimming Injections Gain Back Pounds Four Times Faster Than Those on Conventional Diets
Fresh analysis reveals that individuals who discontinue new GLP-1 drugs like Wegovy and Mounjaro tend to recover reduced body mass much more quickly than those who halt traditional lifestyle programs.
Published data in a leading health publication demonstrates that while obese individuals often shed substantial amounts of their body weight while undergoing treatment, the mass is regained at an average rate of 0.8 kg per month upon discontinuation.
"Users purchasing such treatments must be aware of the potential of quick weight regain when the therapy concludes," warns researcher Dr. Susan Jebb.
Such speed of recovery means a return to starting mass in about 18 months.
Comparing Therapies
The study, which examined 37 of studies involving thousands of participants, compared the effects of these new drugs with older methods.
The team emphasize that people who shed pounds through diet and exercise usually have a more gradual creep back—around 100 grams monthly—post-intervention.
Understanding the Rapid Rebound
Doctors propose the way of the injections is key to understanding the heightened weight return.
GLP-1 drugs imitate a natural hormone called glucagon-like peptide-1, which moderates feelings of fullness.
"Long-term administration of the hormone levels far above than normal might result in the body to generate a reduced amount of its endogenous hormone, and may also lessen sensitivity to its effects," said Dr. Adam Collins, a nutrition specialist.
"Stopping of this hormone supplement means hunger is unsuppressed, making overeating far more likely."
A Lifelong Disease?
Medical guidelines suggest the jabs for people with obesity-related medical conditions, accompanied by recommended lifestyle changes.
A number of clinicians argue that, due to the likelihood of relapse, the therapy might need to be life-long.
This opinion is reinforced by pharmaceutical companies, who state that the findings "underscore the persistent nature of obesity," akin to managing conditions like hypertension.
User Experiences
Users who have discontinued the jabs explain a powerful return of cravings.
"It felt as if something activating and you become ravenous," described an individual.
This challenge is worsened if patients have not adopted permanent dietary or behavioural changes during treatment.
Significant Use
Survey data indicate that a significant number of people in the UK have tried weight-loss jabs in the past year, with interest being substantial.
- Use is higher among females than males.
- The middle-aged age group shows the highest level of interest.
- A large proportion obtain the drugs through private healthcare rather than public health services.
In conclusion, researchers stress that while these medications are potent tools for weight loss, they are not a magic fix and lasting health benefits likely depends on combined behavioural management.
